Reactivation of KIT by secondary mutations in exons 13 or 14 (ATP‐binding pocket) and 17 or 18 (activation loop) is a common resistance mechanism observed in 90% of patients with imatinib‐resistant human gastrointestinal stromal tumours (GIST). The gene discussed is KIT; the disease is gastrointestinal stromal tumor.